Obesity business grows at Novo Nordisk despite Wegovy woes

Novo Nordisk’s obesity care arm continues to grow despite the recent announcement that the company won’t be able to meet the full demand for weight loss drug Wegovy before the second half of 2022.

Photo: Novo Nordisk / PR

Novo Nordisk has had the wind in its sails in 2021, and the pharmaceutical firm’s obesity business sales grew by 50 percent in Danish kroner and 55 percent in current exchange rates (CER), according to the company’s 2021 financial report on Wednesday.

A total of DKK 8.4bn (USD 1.2bn) has been booked by Novo Nordisk’s Obesity Care in 2021, which means the company is well on its way to achieving its 2025 ambition to have doubled its obesity sales from 2019, back when the drug Saxenda contributed to the DKK 5.7bn (USD 865.2m) revenue.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs